to contain an arrhythmogenic centre implicated in neurogenic electrocardiographic changes.²

There is evidence of cortical asymmetry in the regulation of cardiovascular functions: the left insula is concerned mainly with control of parasympathetic cardiac drive, and the right with control of cardiovascular sympathetic tone.^{1,2} Damage to the left insular cortex by stroke may shift sympatho-vagal balance towards increased basal sympathetic tone (a pro-arrhythmic condition), with a decrease in the randomness of HR variability, and may contribute to the excess cardiac mortality following stroke.^{1,2}

Insular infarcts so far reported are caused by artery to artery or cardiac embolisms.⁴ To our knowledge this is the first reported case of insular stroke associated with hyperhomocysteinaemia, which is an emerging independent risk factor for stroke and for vascular recurrence after ischaemic stroke.⁵

In conclusion, persistent neurogenic T wave alteration due to a left insular infarct associated with hyperhomocysteinaemia is reported in this paper. The case underlines the functional complexity of the insular cortex, its role in the generation of cardiovascular changes, and the importance of cardiac monitoring in stroke patients.

J Mandrioli, A Zini, M Cavazzuti, P Panzetti
Department of Neuroscience, University of Modena and Reggio Emilia, Modena, Italy

Correspondence to: Dr Jessica Mandrioli, Neurological Clinic, Department of Neuroscience, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo n. 71, 41100 Modena, Italy; jessicamandrioli@hotmail.com

doi: 10.1136/jnnp.2003.035295

Competing interests: none declared

References

- 1 Oppenheimer SM, Cechetto DF, Hachinski VC. Cerebrogenic cardiac arrhythmias. Cerebral electrocardiographic influences and their role in sudden death. *Arch Neurol* 1990;**47**:513-9.
- 2 Tokgozoglu SL, Batur MK, Topcuoglu MA, et al. Effects of stroke localization on cardiac autonomic balance and sudden death. *Stroke* 1999;**30**:1307-11.
- 3 Augustine JR. Circuitry and functional aspects of the insular lobe in primates including humans. *Brain Res Rev* 1996;**22**:229-44.
- 4 Cereda C, Ghika J, Maeder P, et al. Strokes restricted to the insular cortex. *Neurology* 2002;**59**:1950-5.
- 5 Boysen G, Brander T, Christensen H, et al. Homocysteine and risk of recurrent stroke. *Stroke* 2003;**34**:1258-61.

Prion disease at a regional neuroscience centre: retrospective audit

Timely diagnosis of prion disease is vital if appropriate information and psychosocial support is to be made available to patients and families and appropriate arrangements made for symptomatic treatment and provision of palliative care. For many of these issues optimal management remains uncertain. Guidelines have been published by the Creutzfeldt-Jakob disease (CJD) Support Network¹ suggesting that a "carefully co-ordinated multidisciplinary team" is required to provide a "flexible, family-centred approach, with specialist CJD and palliative care services", with appointment of a key-worker "as soon as possible" to tailor appropriate response. The optimal location of the

palliative care is acknowledged to depend on individual circumstances, but it is recognised that "acute neurology or psychiatric units cannot provide the appropriate environment for longer term care". The guidelines explicitly do not address general palliative nursing care issues.

Most reports on cohorts of patients with prion disease have emanated from national referral centres. However, it is widely accepted that delivery of patient care close to or at home is the ideal. In many cases, this means regional neurological facilities. We undertook an audit of all pathologically confirmed prion disease cases seen in the catchment area of the Walton Centre for Neurology and Neurosurgery (WCNN), a regional neuroscience centre in Liverpool, UK, serving a population of around 3 million people and 14 district general hospitals (DGHs) in northwest England and north Wales, over a 12 year period (1990-2001) prior to publication of the CJD Support Network guidelines, to ascertain what management plans had been formulated or implemented for patients with prion disease.

Cases were identified through individual consultant neurologists and from the National Creutzfeldt-Jakob Disease Surveillance Unit (NCJDSU) in Edinburgh (Professor R G Will, personal communication). Symptomatic interventions and management of the terminal phase of the illness were ascertained by case note review, in particular, decisions about patient hydration and "do not resuscitate" (DNR) orders.

From 1990 through 2001, 82 patients with suspected CJD were referred from the Mersey Region to the NCJDSU (41 males, 41 females; average age 60.1 (SEM 19.7) years, range 14-90; eight patients ≤ 30 years). Of these, 65 referrals were made after 1995 when the epidemic of variant CJD (vCJD) in the UK began. A total of 66 patients (80%) presented initially to non-neurologists and 44 referrals were of inpatients at WCNN, usually transferred from DGHs by visiting neurologists. A total of 38 cases were referred to NCJDSU directly from DGHs or from Alder Hey Children's Hospital, Liverpool.

Prion disease was confirmed pathologically in 43/82 referrals, giving an overall diagnostic accuracy of 52%. Of the cases with confirmed prion disease, 33 had sporadic CJD, 8 had vCJD (some already reported^{2,3}), and 2 had iatrogenic disease. There were no familial cases. Three patients never saw a neurologist. Of the 39 non-prion cases, eight were found to have alternative diagnoses only at post mortem, principally Alzheimer's disease and dementia with Lewy bodies.

In none of the 43 cases with pathologically confirmed prion disease could a keyworker coordinating care be identified from case note review. Various symptomatic treatments for myoclonus, the commonest movement disorder, were tried, namely sodium valproate, clonazepam, baclofen, diazepam, and phenytoin. An empirical course of steroids to treat an undiagnosed vasculitis or autoimmune disease was given in a few cases, without benefit.

It was recorded in the notes of 32 patients (75%) that when oral fluid intake proved insufficient, fluids were given by the subcutaneous, nasogastric, or intravenous route to maintain adequate hydration. The families of only two patients opted to have a percutaneous endoscopic gastrostomy (PEG) tube placed: in one patient this continued to be in use for nearly three years, in the other, only for a period of weeks before death.

Various symptomatic treatments were used to relieve distress in the terminal phase of disease, namely diamorphine, midazolam, and cyclomorphine. In only nine cases (21%) was there any comment about cardio-respiratory resuscitation policy. In seven cases it was explicitly stated that the patient was not for resuscitation; in one case the family did not agree to a DNR policy, and in one case it was not clear what policy, if any, was agreed. All the patients died in hospital; none went to a hospice. One patient with sporadic CJD temporarily went to a nursing home, before returning to hospital to die. Nursing home placement was considered for one other patient, but the family preferred the patient to stay in hospital.

Although there are hopes for the efficacy of agents such as mepacrine and PPS, disease modifying treatment for prion disease does not currently exist. Hence, once the diagnosis is made, management is symptomatic (for example, for movement disorders, especially myoclonus, seizures, autonomic and sleep disorders, swallowing problems, and pain) and care is palliative. This being the case, provision of information and psychosocial support is of paramount importance. In the UK, patients and carers may contact various resources, such as the NCJDSU and the National Care Co-ordinator,⁴ the National Prion Clinic, the CJD Support Network, the Human BSE Foundation, and the CJD Advice Network (Department of Health). However, these agencies may not be able to provide local solutions to the care needs of patients and families affected with prion disease. Difficulties in finding appropriate locations for palliative care of patients with vCJD have been documented,⁵ leading the Department of Health to create a National Care Package.⁴

The heterogeneity of management revealed by our audit most likely reflects uncertainty about the optimal management of prion disease, and the absence of specific guidelines during the time covered by the audit. The development of guidelines and integrated care pathways which can address the specific issues facing patients with prion disease and their relatives in a comprehensive yet flexible manner may be helpful, although again disease rarity suggests that completing the audit cycle may be a long process. Coordination and support from at least one dedicated health professional in each regional neuroscience centre, to ensure implementation of guidelines¹ and to work with local agencies such as palliative care teams, currently seems an appropriate response.

Acknowledgements

We thank Professor R G Will, National CJD Surveillance Unit, Edinburgh, for supplying details of cases referred from this region, and also our colleagues at WCNN for supplying patient details. Pauline Kelly, Ann Noble, Julie Richardson, and Lynette Roberts helped to recover hospital notes.

A J Larner, M Doran

Cognitive Function Clinic, Walton Centre for Neurology and Neurosurgery, Liverpool, UK

Correspondence to: Dr Larner, Cognitive Function Clinic, Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool, L9 7UJ, UK; a.larner@thewaltoncentre.nhs.uk

doi: 10.1136/jnnp.2003.035345

Competing interests: none declared

References

- 1 *Creutzfeldt-Jakob disease (CJD): information and nursing care guidelines*. London: Alzheimer's Society, 2002.
- 2 Silverdale M, Leach JP, Chadwick DW. New variant Creutzfeldt-Jakob disease presenting as localization-related epilepsy. *Neurology* 2000;**54**:2188.
- 3 Lorrains JW, Henry C, Agbamu DA, et al. Variant Creutzfeldt-Jakob disease in an elderly patient. *Lancet* 2001;**357**:1339-40.
- 4 Weller B, Will R, McLean G. Variant Creutzfeldt-Jakob disease: development of a national coordinated care programme [abstract]. *J Neurol Neurosurg Psychiatry* 2003;**74**:405.
- 5 Douglas MJ, Campbell H, Will RG. Patients with new variant Creutzfeldt-Jakob disease and their families: care and information needs. Edinburgh, Department of Public Health Service, Edinburgh University, National CJD Surveillance Unit, 1999 (website: www.cjd.ed.ac.uk/carerrep.html).

BOOK REVIEWS

Myopathies in clinical practice

Edited by Phillip R J Barnes and David Hilton-Jones. Published by Martin Dunitz, London, 2003, £49.95 (hardcover), pp 161. ISBN 1-899066-71-3

Text books come in two forms; some attempt to tell you all there is to know while others try and tell you what you need to know. The editors' introduction to this book suggests that it falls into the latter category but in fact it "punches above its weight" with regard to the depth of coverage in a number of the chapters and includes observations, reminders, and pointers that all myologists, let alone general neurologists, will find extremely valuable.

Beyond the superficial level, neuromuscular disorders are complicated mainly because we now know so much about their underlying molecular biology. This book goes as far as reasonably possible in making these complexities understandable. It is divided into two sections. The first deals with basic principles, including clinical assessment and the investigation of muscle disease. The writing style is direct and almost conversational—in the style of a tutorial, which many

will find attractive. The section on investigation of muscle disease is particularly clear and comprehensive with a helpful exposition on the basics of electromyography in muscle disease and neuromuscular transmission disorders. This section concludes with a chapter on the principals of therapy of neuromuscular disease—a topic which is usually tucked away in the back of a more typical text book—perhaps reflecting the Editors very positive attitude to this aspect of this speciality. To quote them, to say that there is "nothing that I can do for you" is indeed a sad reflection on the lack of a holistic or rehabilitative approach from the clinicians involved.

The second section deals in turn with the muscular dystrophies, inflammatory myopathies, muscle channelopathies, metabolic myopathies, and the toxic and endocrine myopathies, and concludes with chapters on congenital myopathies and miscellaneous muscle disorders. The final chapter on neuromuscular junction disorders is included for the sake of completeness. Each of these chapters is to a similar high standard, although I would comment that there is no obvious logic in the way that these are ordered in the book. There is also a comprehensive index that proves efficient on several occasions.

This volume is commendably short and the text is arranged in a double column format. The production is lavish, profusely illustrated in colour with many diagrams and text boxes, which are beautifully clear. For general neurologists, I think this book will have few serious rivals as a convenient, modern, and comprehensive source of information on the most important aspects of muscle disease, and I can recommend it most highly.

R J M Lane

The central nervous system structure and function—third edition

Edited by Per Brodal. Published by Oxford University Press, Oxford, 2003, £49.50 (hardback), pp 495. ISBN 0-19-516560-8

This third edition of Per Brodal's book "*The central nervous system: structure and function*",

last edited in 1998, attests to the efforts of the author to keep up with the rapid pace of development in the field of neurosciences. Many of us probably remember the repulsive effect of overwhelming details in some textbooks of neuroanatomy or neurophysiology, that fail to be relevant in clinical practice. Here, the dynamic and concise presentation of both the structure and the function of the central nervous system at different levels (molecular, cellular, and systems), with special emphasis on how the different components are connected and interact, manages to captivate the reader. Beside key information on the fundamental background, there are numerous clinical examples that will help the medical student to bridge the gap between basic and clinical neuroscience. The book also offers several didactic drawings and figures, and, for the reader interested in a particular topic, more detailed sections are placed in highlighted boxes. In addition, a rich selection of references recommended by the author on each topic are listed at the end of the book. The third edition includes two new sections on the vestibular system and the control of eye movements.

The principal aim of the author, who perpetuates a familial tradition (the first Norwegian edition of the book was run by Per Brodal's father in 1949), is "to stimulate understanding rather than memorization of isolated facts" and "[to foster] a realistic attitude toward our still limited ability to explain the marvels of the human brain."

I recommend this book to all medical students, and also to more advanced clinicians who wish to refresh their knowledge in basic neurosciences or as a useful tool for teaching their younger colleagues.

S Debette

CORRECTION

doi: 10.1136/jmg.2003.034827corr1

In the Letter by Jardine *et al* (*J Neurol Neurosurg Psychiatry* 2004;**75**:1651) the initials of Krediet were published incorrectly. The correct initials are C T P.